Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.

Parameswaran N, Bartel CA, Hernandez-Sanchez W, Miskimen KL, Smigiel JM, Khalil AM, Jackson MW.

Sci Rep. 2019 Sep 16;9(1):13396. doi: 10.1038/s41598-019-49475-5.

2.

Assay for Transposase-Accessible Chromatin Using Sequencing (ATAC-seq) Data Analysis.

Miskimen KL, Chan ER, Haines JL.

Curr Protoc Hum Genet. 2017 Jan 11;92:20.4.1-20.4.13. doi: 10.1002/cphg.32.

PMID:
28075484
3.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.

4.

Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.

5.

Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer.

Merry CR, McMahon S, Thompson CL, Miskimen KL, Harris LN, Khalil AM.

Breast Cancer Res Treat. 2015 Apr;150(2):321-34. doi: 10.1007/s10549-015-3327-1. Epub 2015 Mar 8.

PMID:
25749757
6.

Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer.

Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW.

Mol Cancer Res. 2014 Aug;12(8):1156-65. doi: 10.1158/1541-7786.MCR-13-0289. Epub 2014 Apr 15.

7.

Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.

Cipriano R, Bryson BL, Miskimen KL, Bartel CA, Hernandez-Sanchez W, Bruntz RC, Scott SA, Lindsley CW, Brown HA, Jackson MW.

Oncogene. 2014 Jun 19;33(25):3298-306. doi: 10.1038/onc.2013.293. Epub 2013 Aug 5.

8.
9.

FAM83B mediates EGFR- and RAS-driven oncogenic transformation.

Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, Brown HA, Stark GR, Jackson MW.

J Clin Invest. 2012 Sep;122(9):3197-210. doi: 10.1172/JCI60517. Epub 2012 Aug 13.

10.

Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.

Li G, Miskimen KL, Wang Z, Xie XY, Tse W, Gouilleux F, Moriggl R, Bunting KD.

Leukemia. 2010 Aug;24(8):1397-405. doi: 10.1038/leu.2010.131. Epub 2010 Jun 10.

11.

Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5.

Li G, Wang Z, Miskimen KL, Zhang Y, Tse W, Bunting KD.

PLoS One. 2010 Feb 10;5(2):e9152. doi: 10.1371/journal.pone.0009152.

12.

STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Li G, Miskimen KL, Wang Z, Xie XY, Brenzovich J, Ryan JJ, Tse W, Moriggl R, Bunting KD.

Blood. 2010 Feb 18;115(7):1416-24. doi: 10.1182/blood-2009-07-234963. Epub 2009 Dec 14.

Supplemental Content

Loading ...
Support Center